Transplant Complications Working Party (TCWP)
Type d'étude:
Numéro de l'étude:
2019000902
Type de traitement à base de cellules souches:
Allogeneic
Maladies:
Titre court:
ECP combination Study
Objectif principal:
The primary objective of the study is to compare and to evaluate the safety and efficacy of patients receiving ECP and/or new treatments in acute and chronic GvHD
Principaux critères d'inclusion:
-Adult patients;
-Patients who develop acute SR-GvHD after first HSCT and there is a minimum of 6 months follow up data in the database
Patients who initiate treatment with ECP or Ruxolitinib within 60 days of onset of SR aGvHD
aGVHD Grade: II-IV only at time of treatment initiation
-Patients who develop chronic SR-GvHD after first HSCT and there is with a minimum of 1 year follow up data in the database
Patients who initiate treatment with ECP or Ruxolitinib or Ibrutinib within 1 year of the onset of SR-cGvHD
cGVHD Severity: moderate to severe only at time of treatment initiation
-Patients who develop acute SR-GvHD after first HSCT and there is a minimum of 6 months follow up data in the database
Patients who initiate treatment with ECP or Ruxolitinib within 60 days of onset of SR aGvHD
aGVHD Grade: II-IV only at time of treatment initiation
-Patients who develop chronic SR-GvHD after first HSCT and there is with a minimum of 1 year follow up data in the database
Patients who initiate treatment with ECP or Ruxolitinib or Ibrutinib within 1 year of the onset of SR-cGvHD
cGVHD Severity: moderate to severe only at time of treatment initiation
Pays:
Danemark
France
Allemagne
Grèce
Hongrie
Israël
Italie
Pays-Bas
Norvège
Pologne
Roumanie
Fédération de Russie
Espagne
Turquie
Royaume Uni
Investigateur principal:
Dr. Olaf Penack
Coordinateur EBMT de l'étude:
Jessica Lemaitre
E-mail du coordinateur de l'étude:
jessica.lemaitre@upmc.fr